Expertise in
10
conditions

Dr. David S. Hanson

Hematology
Hematology Oncology Associates Of Baton Rouge
4950 Essen Ln, 
Baton Rouge, LA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
10
conditions
Hematology Oncology Associates Of Baton Rouge
4950 Essen Ln, 
Baton Rouge, LA 

Overview

David Hanson is a Hematologist practicing medicine in Baton Rouge, Louisiana.

Dr. Hanson is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Hypereosinophilic Syndrome, Acute Eosinophilic Pneumonia, and ALK-Positive Non-Small Cell Lung Cancer.

He is actively involved in clinical research, co-authoring 4 peer reviewed articles and participating in 73 clinical trials. Dr. Hanson is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in LA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Hematology Oncology Associates of Baton Rouge
4950 Essen Ln, Baton Rouge, LA 70809

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

72 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Procedure, Other
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
View 8 Less Clinical Trials

4 Total Publications

Financial Hardship Among Patients With Early-Stage Colorectal Cancer.
Financial Hardship Among Patients With Early-Stage Colorectal Cancer.
Journal: JAMA network open
Published: September 17, 2024
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Hematology Oncology Associates Of Baton Rouge

4950 Essen Ln, 
Baton Rouge, LA 
 (0.1 miles away)
225-767-0847
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Dalovisio is a Hematologist practicing medicine in Baton Rouge, Louisiana. He has been practicing medicine for over 17 years. Dr. Dalovisio is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Dalovisio is currently accepting new patients.

Expertise in
55
conditions
Dr. Siva Sankar-Yadlapati
Hematology | Oncology
Expertise in
55
conditions
Dr. Siva Sankar-Yadlapati
Hematology | Oncology
Referral may be required

Hematology Oncology Associates Of Baton Rouge

4950 Essen Ln, 
Baton Rouge, LA 
 (0.1 miles away)
225-767-0847
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Siva Sankar-Yadlapati is a Hematologist and an Oncologist practicing medicine in Baton Rouge, Louisiana. Dr. Sankar-Yadlapati is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Sickle Cell Disease, Acute Myeloblastic Leukemia without Maturation, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration. Dr. Sankar-Yadlapati is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Hematology Oncology Associates Of Baton Rouge

4950 Essen Ln, 
Baton Rouge, LA 
 (0.1 miles away)
225-767-1311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bryan Bienvenu is a Hematologist practicing medicine in Baton Rouge, Louisiana. Dr. Bienvenu is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Relapsed Refractory Multiple Myeloma (RRMM), Multiple Myeloma, and Non-Hodgkin Lymphoma. Dr. Bienvenu is currently accepting new patients.

Frequently Asked Questions about Dr. David S. Hanson

How do I make an appointment with Dr. David S. Hanson?

You can book an appointment with Dr. David S. Hanson by calling their office at 225-767-1311. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David S. Hanson a top-rated expert for Polycythemia Vera?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David S. Hanson is classified as an Advanced expert for Polycythemia Vera, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David S. Hanson specialize in?

While Dr. David S. Hanson is a Hematology, they have specific expertise in Polycythemia Vera, Hypereosinophilic Syndrome, and Acute Eosinophilic Pneumonia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. David S. Hanson participate in research or clinical trials?

Yes. Dr. David S. Hanson has published 4 articles and abstracts on conditions like Polycythemia Vera. You can view a list of Dr. David S. Hanson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David S. Hanson accept my insurance?

Dr. David S. Hanson accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 225-767-1311 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hanson's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 41 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile